Patients: A 29-year-old Caucasian woman (patient 1) and a 23-year-old Caucasian woman (patient 2).
Results of a second HPV-4C FISH assay showed numerous (14.6%) cells with a gain of 3q26 and 5p15 regions (Image 2A). Repeat cervical and endocervical biopsies showed scant atypical glands in otherwisegenerous biopsies (Image 2B). Supported by abnormal p16 and Ki-67 immunohistochemical staining results (Image 2C and 2D) and the knowledge of the abnormal FISH assay results, the pathologist diagnosed the patient with endocervical adenocarcinoma in situ (AIS). The results of a subsequent LEEP confirmed the diagnosis of endocervical adenocarcinoma in situ with negative resection margins. Persistently negative Pap cytology results, which reveal positivity for high-risk HPV, may be vexing for the health care professional, worrisome for the patient, and often followed up by HPV genotyping or repeat cytology in 1 year. This may mean unnecessary concern on behalf of the patient or a yearlong delay in the treatment of a high-grade lesion.
Hematoxylin-eosin (H&E) examination of tissue biopsies of the cervix and endocervical canal represents the gold standard for the assessment of cervical disease. However, based on experience gained in a busy gynecologic pathology practice, microscopic interpretation of the biopsies may be subject to sampling bias, scant volume, and technical difficulties such as tangential sectioning or biopsy artifact. Such limitations, even with the usage of ancillary studies (eg, p16, which is a biomarker for the presence of high-risk HPV, and Ki-67, a proliferative index stain) may lead to a less-than-satisfying diagnosis for the health care professional and pathologist. Although ambiguous diagnoses are rarely made, they are sometimes unavoidable and are often delivered with the recommendation to repeat the biopsy or to closely follow the patient using other methods (such as cytologic and/or HPV testing.)
Finally, squamous dysplasia is a moving target in that it may regress. A total of 40% of cases of CIN 2 may regress during a 2 year period, even without treatment. 6 This means that the affected patients may have a history of a high-grade cytology results (high-grade squamous intraepithelial lesion [HSIL]) and subsequent negative biopsy results (due to the regression of disease), which can be troubling for the health care professional and the patient. Also, even with biopsy confirmation of high-grade cervical disease, these lesions may then subsequently regress, meaning that the patient may be overtreated with cervical excision in the interim.
2.
The limitations discussed in possible answer 1 show unmet prognostic/predictive and diagnostic needs in the process of cervical-cancer screening. Recently, human papilloma virus (HPV) testing has evolved, allowing evaluation for the presence of HPV messenger RNA (mRNA), rather than HPV DNA, the former of which looks for the presence of the oncogenic proteins E6 and E7 produced during integration of HPV DNA into the host genome. These tests may be more specific for a clinically meaningful, integrated HPV infection 7 (rather than merely the presence of transient HPV DNA). However, the presence of HPV mRNA does not guarantee progression to a high-grade squamous (or glandular) lesion. Therefore, a test that could help triage challenging clinical scenarios such as those described earlier herein would be desirable to guide treatment by healthcare professionals and to support the diagnoses made by pathologists.
HPV infection is only the first step of many in the development of cervical cancer. Advancement to a higher level of disease (ultimately becoming an invasive carcinoma) requires persistence of the infection; integration of the viral DNA into the host genome; and overexpression of the oncogenic proteins E6/E7, which then subvert normal cellcycle control mechanisms and cause genomic instability, leading to further tumor development. Using FISH technology to assess for genomic instability in the form of nonrandom chromosomal abnormalities may provide the solution to challenging clinical settings. For example, these tests may serve as a next-level mode of triage after an atypical cytologic testing result or may support a difficult diagnosis based on scant tissue, as evidenced in the patient examples outlined herein.
Numerous nonrandom chromosomal abnormalities are associated with the development of cervical carcinoma. Colloquially, some of the most common include gain of 1q, 3q, 5p, 8q, and 20q regions; gain of 1p, 9q, 15q, 17q, and 19q regions is observed less frequently. Typically, chromosomal losses are also observed, although gains are more easily assessed with FISH than losses due to artificial loss of a target with overlapping probe signals or other artifacts of analysis. The selection of the regions 3q, 5p, 20q
and centromere 7 as targets in this test is based on the most frequent gains across numerous cases of HPV-associated carcinomas. programs have had a significantly greater effect on cervical squamous carcinomas than adenocarcinomas. This result may be occurring because glandular neoplasia is more difficult to identify morphologically on cervical Papanicolaou (Pap) tests and because it is more difficult to obtain specimen material from the endocervical canal (in terms of anatomical location and the fact that glandular neoplasia may exist deep within endocervical crypts.) Human papilloma virus (HPV) DNA has been identified in a wide range of cervical adenocarcinomas (30% to 90%), unlike squamous-cell carcinomas, of which 99% of cases are associated with HPV. gene, a biomarker for advanced cervical disease, has mechanisms of development in cervical adenocarcinomas that are similar to those found in high-grade squamous lesions (even in adenocarcinomas, which tested negative for high-risk HPV, in this study).
In summary, the HPV-4C assay, which uses the 4 probes 3q26, 5p15, 20q, and centromere 7, designed by Cancer Genetics Inc, has the ability to identify abnormal gains of 4 of the most common nonrandom chromosomal abnormalities observed in the development of cervical cancer (squamous and endocervical glandular types). Using this test can serve as an additional and more specific personalized method of triage in challenging clinical scenarios, particularly when histologic or cytologic testing provide unclear results.
